Medicine

In their July 28 seminar, the Frontline Doctors Group led by Dr Simone Gold, have put some plausible mechanisms for HCQ based cocktails on the table. These were noted on in an augmentation to an earlier post, but deserve headlining in their own right: Dr Frieden OP: >>I have found at Bit Chute, a July 28 Frontline Doctors seminar which describes several mechanisms of action. Accordingly, I take liberty to annotate a screenshot, summarising several mechanisms of action described by these Doctors [cf. here for their references], but which are hard to find because of now almost pervasive censorship: I add, that the above suggests a fairly similar viral attack process to the West Nile Virus (which is also an Read More ›

One of the key steps in dismissing evidence of efficacy of hydroxychloroquine-based cocktails in treating early stageCovid-19 for patients in vulnerable groups on an outpatient basis is the use of the premise that such evidence is of low quality as it does not match the “gold standard” of placebo-controlled, randomised tests (often. RCT’s). However, observations are observations, natural regularities are often observable from the first few trials, evidence is evidence, ethical and practical considerations are real, and valid scientific methods do not reduce to applied statistics. It is in that context that we should attend carefully to remarks by Dr Thomas Frieden, writing in NEJM 3 1/2 years ago, in terms that uncannily anticipate our current woes: Despite their strengths, Read More ›

It’s worth headlining from the CV19 thread: Jerry, 579: >>Dr. Risch strikes back. https://washex.am/2DFxdij Hydroxychloroquine works in high-risk patients, and saying otherwise is dangerous As of Wednesday, some 165,000 people in the United States have died from COVID-19. I have made the case in the American Journal of Epidemiology and in Newsweek that people who have a medical need to be treated can be treated early and successfully with hydroxychloroquine, zinc, and antibiotics such as azithromycin or doxycycline. I have also argued that these drugs are safe and have made that case privately to the Food and Drug Administration. The pushback has been furious. Dr. Anthony Fauci has implied that I am incompetent, notwithstanding my hundreds of highly regarded, methodologically Read More ›

I note, from OWID, today August 13. First, case fatality rate vs population’s median age, though this is oldish data now . . . however exceptionally poor management by the US — an obvious implied thesis — should have been obvious even then: Next, case fatality rate overall — a metric dependent on degree of testing, how deaths are attributed and tracked: In both of these, the USA — subject of an in thread debate — is unexceptional. In particular, it sits spot on for median age of population. END PS: Let me add from Worldometers for the USA, noting that deaths also show much the same pattern: Here, as we went into April, there was a fundamental shift in Read More ›

As a FYI, we need to understand the pattern of such diseases, so courtesy Yandex Image search (Google did an obvious results suppression): This leads to the simplified U/L trajectory description. If a vulnerable patient catches, things tend to get worse over several days, potentially leading to a crisis from immunity system over-reaction and/or secondary infection (“complications”). That can lead to flat-lining, the L, death. But if one makes it through the trough, a recovery period extends the disease process, the U trajectory. BTW, to see the U/L, invert the black line that rises with severity on the chart. Shouldn’t a deterioration lead to sinking? U/D, HT Jerry and MedCram/Mina: Let’s look at a plot of viral load vs time Read More ›

IHU- Méditerranée Infection, Marseille, is a significant French research institute that has continued its work on CV 19. For the record, here are excerpts from some recent work, headlined from threads where such would be buried: EXH 1: >>COVID-IHU #15 Version 1 du 27 Mai 2020 Early diagnosis and management of COVID-19 patients: a real-life cohort study of 3,737 patients, Marseille, France Abstract Background: In our institute in Marseille, France, we proposed early and massive screening for coronavirus disease 2019 (COVID-19). Hospitalization and early treatment with hydroxychloroquine and azithromycin (HCQ-AZ) was proposed for the positive cases. Methods: We retrospectively report the clinical management of 3,737 patients, including 3,054 (81.7%) treated with HCQ-AZ for at least three days and 683 (18.3%) Read More ›